About: http://data.cimple.eu/news-article/20c0ca63db72694b07857c72c3e4dbb7d4bfde1381aa8b5d1944347a

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/20c0ca63db72694b07857c72c3e4dbb7d4bfde1381aa8b5d1944347a Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Deliveries of the Johnson & Johnson coronavirus vaccine in the United States are set to drop off sharply next week, US health authorities said Friday, stoking further unease about the pharmaceutical giant's production abilities. The number of J&J shots distributed to US states will fall from 4.9 million in the week ending April 5 to just 700,000 by the week ending April 12, according to data released by the Centers for Disease Control and Prevention (CDC). The company had promise to deliver "at or near" 100 million of its one-shot doses by the end of May, and is still vowing to meet that target. But last week it emerged that a batch of some 15 million doses had been accidentally spoiled at a plant in Baltimore. Ingredients meant to be used in another vaccine, made by AstraZeneca, were mixed up with those destined for the J&J shot, The New York Times reported. The mix-up was detected during quality controls and the defective doses never left the factory, which is still waiting to be officially authorized to supply the vaccine. Since then, production of AstraZeneca's vaccine has been moved away from the Baltimore plant, managed by partner company Emergent BioSolutions, and J&J officials have been dispatched to oversee operations. Johnson & Johnson said Saturday it was "assuming full responsibility" for the incident, vowing to work in "full cooperation" with the US Food and Drug Administration (FDA) to obtain authorization to produce its vaccine in the Baltimore facility. Johnson & Johnson's vaccine, which has the major logistical advantage of being administered in a single dose, was granted emergency use authorization in the United States at the end of February, following approval for rivals Pfizer/BioNTech and Moderna. J&J delivered 20 million doses in March to the United States, meeting its production target, and "24 million is the target that the company has committed to for April," said Jeff Zients, the White House coordinator for the fight against Covid-19, last week. "Moderna and Pfizer are now in a steady cadence [of delivery], week to week. That's not something that Johnson & Johnson has yet achieved," he said. la/cjc/jh/dw
schema:headline	Sharp drop in J&J vaccine delivery in the US next week: CDC data
schema:mentions	Jeffrey Zients Pharmaceutical industry Johnson & Johnson Baltimore The New York Times AstraZeneca Food and Drug Administration Centers for Disease Control and Prevention White House Pfizer Vaccine United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 The Mix-Up Emergent BioSolutions Cadence Full Cooperation Multivibrator Data warehouse
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-04-09 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	83 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software